Sign In
NASDAQ:ASMB
Assembly Biosciences Stock News
$16.21
-0.110 (-0.674%)
At Close: Dec 06, 2024
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
10:47am, Monday, 16'th Sep 2024
Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
08:00am, Wednesday, 22'nd May 2024
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at t
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
04:05pm, Wednesday, 08'th May 2024
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, to
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
04:05pm, Thursday, 28'th Mar 2024
SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,
Assembly Biosciences Announces Effective Date of Reverse Stock Split
08:00am, Thursday, 08'th Feb 2024
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –
Assembly Biosciences Provides Anticipated Development Milestones for 2024
08:00am, Thursday, 04'th Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral d
5 Penny Stocks With Big Black Friday Stock Market News
09:50am, Friday, 24'th Nov 2023
Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news,
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 10'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral d
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
08:00am, Wednesday, 08'th Nov 2023
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRA
Why Are Stocks Down Today?
11:17am, Tuesday, 17'th Oct 2023
Stocks are down today and investors wondering why are in the right place as we have all the details they need to know about on Tuesday! The big reason that stocks are down today has to do with the lat
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
10:59am, Tuesday, 17'th Oct 2023
Assembly Biosciences (NASDAQ: ASMB ) stock is taking off on Tuesday after announcing a massive collaboration with Gilead Sciences (NASDAQ: GILD ). According to a press release, these two companies hav
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
08:00am, Wednesday, 11'th Oct 2023
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company's interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLO
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
08:00am, Monday, 02'nd Oct 2023
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected –
